Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea

International Journal of Hematology

Volumn 82, Issue 3, 2005, Pages 251-258

  Moeremans, Karen ^a,b,f   Annemans, L ^a,b   Ryu, Ji So ^c   Choe, Kang Won ^d   Shin, Wan Shik ^e  

^a HEDM   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f NONE   (Belgium)

Author keywords

Cost effectiveness; Immunocompromised; Itraconazole; Systemic fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CASPOFUNGIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; IVITRA; POTASSIUM SPARING DIURETIC AGENT; SODIUM; VORICONAZOLE;

ARTICLE; BONE MARROW TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; ELECTROLYTE DISTURBANCE; FEVER; HEALTH CARE COST; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; SOUTH KOREA; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; COSTS AND COST ANALYSIS; HUMANS; ITRACONAZOLE; KOREA; MYCOSES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 27644548144     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30504     Document Type: Article

References (46)

1. Meyers J. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990;17(suppl 6):10-13.
2. De Bock R, Marinus A, Nagler C, et al. EBMT/EORTC study on invasive fungal infection (IFI) in bone marrow transplant (BMT) patients [abstract]. Bone Marrow Transplant. 1995;15(suppl 2):104.
3. Warnock DW. Fungal complications of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother. 1995;36(suppl B): 73-90.
4. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
5. Working Party of the British Society for Antimicrobial Chemotherapy. Therapy of deep fungal infection in haematological malignancy. J Antimicrob Chemother. 1997;40:779-788.
6. Marr KA. Empirical antifungal therapy: new options, new trade-offs. N Engl J Med. 2002;346:278-280.
7. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-111.
8. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-672.
9. Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis. 1991; 13:496-503.
10. Ruhnke M, Böhme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82(suppl 2):S141-S148.
11. Walsh TJ, Finberg RW, Arndt C, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771.
12. Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003; 82(suppl 2):S105-S117.
13. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996;10:365-400.
14. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991;28:83-91.
15. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-718.
16. Goff DA, Sierawski SJ. A clinical and economic analysis of amphotericin B lipid complex (ABLC) versus amphotericin B. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 1998; Washington, DC. Abstract O4.
17. Tollemar J, Ringdén O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Saf. 1995;13:207-218.
18. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Intern Med. 2000;160:2659-2664.
19. Walsh TJ, Pappas P, Winston DJ, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
20. Winston DJ, Hathorn JW, Schuster MG, Schilder GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-289.
21. Leather HL, Wingard JR. Prophylaxis, empirical therapy, or preemptive therapy of fungal infections in immunocompromised patients: which is better for whom? Opin Infect Dis. 2002;15: 369-375.
22. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infections in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med. 1994;120:913-918.
23. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990;26:561-566.
24. van't Wout JW, Novakova I, Verhagen CAH, Fibbe WE, de Pauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991;22:45-52.
25. Denning DW, Lee JY, Hosteller JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135-144.
26. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med. 2001; 135:412-422.
27. Boogaerts M, Garber G, Winston D, et al. Itraconazole compared with amphotericin B as empirical therapy for persistent fever of unknown origin in neutropenic patients [abstract]. Bone Marrow Transplant. 1999;23(suppl 1). Abstract 358.
28. Pauker SJ, Kassirer JP. Decision analysis. N Engl J Med. 1987;316: 250-258.
29. Stewart A, Powles R, Hewetson M, Antrum J, Richardson C, Mehta J. Costs of antifungal prophylaxis after bone marrow transplantation: a model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections. Pharmacoeconomics. 1995;8:350-361.
30. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. Pharmacoeconomics. 1997;12:121-129.
31. Evans C, Crawford B. Expert judgement in pharmacoeconomic studies: guidance and future use. Pharmacoeconomics. 2000;17: 545-553.
32. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74: 979-983.
33. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155-1163.
34. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Boldwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 1996;18:265-271.
35. Wakerly L, Craig A-M, Malek M, et al. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. J Hosp Infect. 1996;33:35-48.
36. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplants with systemic mycosis. Pharmacoeconomics. 1992;2:500-508.
37. Bennet J. Editorial response: choosing amphotericin B formulations-between a rock and a hard place. Clin Infect Dis. 2000;31: 1164-1165.
38. Boogaerts M. Pharmacoeconomic evaluation of AMBISOME in febrile neutropenia. In: Abstracts from the 35th Annual Scientific Meeting of the British Society for Haematology; 1996.
39. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000;18:2476-2483.
40. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother. 2002;49(suppl S1): 81-86.
41. Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics. 2004;22:421-433.
42. Annemans L, Moeremans K, Milligan DW, Kibbler C, Van Gool R. Economic evaluation of intravenous itraconazole in presumed systemic fungal infections. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 1999; San Francisco, California. Abstract 1867.
43. Moeremans K, Annemans L, Vandoros C, Liaropoulos L. Economic evaluation of intravenous itraconazole in presumed systemic fungal infections in neutropenic patients in Greece. Value Health. 2004;7:639.
44. Potter M, Donnelly JP. The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol. 2004;111:175-180.
45. Bates DW, Yu DT, Chertow G, et al. Resource utilization and amphotericin B associated nephrotoxicity. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 1998; Washington, DC. Abstract Oil.
46. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-693.